Investigating the therapeutic potential for pharmacologic targeting of S6K1 in PTEN-deficient glioblastoma, we previously found that co-targeting AXL with S6K1 induced cytotoxic responses selectively in PTEN-deficient glioblastoma cells (28). This evidence concerns the gene RPS6KB1 and glioblastoma.